key: cord-0765897-n4y67x5p
authors: Napolitano, Maddalena; Fabbrocini, Gabriella; Patruno, Cataldo
title: Potential role of Janus kinase inhibitors in COVID-19
date: 2020-04-24
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.04.098
sha: 041da5653da28039cdc4aae02ac994c9e321ee32
doc_id: 765897
cord_uid: n4y67x5p

nan

Authors: Maddalena Napolitano 1 , Gabriella Fabbrocini 2 , Cataldo Patruno 3 Affiliation: 1 Recently, Richardson et 2 al proposed baricitinib as potential treatment for pneumonia during COVID-19, because it would be capable to reduce the ability of the virus to infect lung cells. 2 The lung is particularly prone to SARS-CoV-2 infection probably for the presence of AT2 cell. This cell expresses on its surface the protein ACE2, a receptor used by the virus to invade the host. 2 One of the known regulators of endocytosis is the AP2-associated protein kinase 1 (AAK1). 2 Disruption of AAK1 might, in turn, interrupt the passage of the virus into cells and also the intracellular assembly of virus particles. 3 Baricitinib on therapeutic dosing is reported to be able to inhibit AAK1 functions and to bind the cyclin G-associated kinase, another regulator of endocytosis of virus. 3 In both phase II and phase III trials on atopic dermatitis (AD) baricitinib had a good safety profile: headache, nasopharyngitis, and increase in CPK levels were the most common adverse events. 4 The increased Incidence of infective diseases such as reactivation of Varicella Zoster, Herpes Simplex and Epstein Barr Virus strains reported in trials for rheumatoid arthritis, was not observed in AD patients. 4 Upadacitinib is a selective JAK1 inhibitor and is currently being investigated for AD treatment. 4

Preclinical research showed that disruption of JAK1 signaling induced by upatacitinib reduced the expression of T-helper(Th)-2 and Th22 cytokines, but also the levels of interleukin (IL)-6, through inhibition phosphorylation of STAT3. 5 It is also known that IL-6, plays a central role in the "cytokine storm" damaging lung in Covid-19 patients. 1 Recently, tocilizumab a monoclonal antibody that competitively inhibits the binding of IL-6 to its receptor has been used to treat complications of COVID-19 induced pneumonia and China's National Health Commission and the Italian Medicines Agency approved the tocilizumab use in severe patients with extensive lung disease and with elevated IL-6 levels detected by the laboratory.

All these preclinical data seem to suggest that treatment with both baricitinib and upatacitinib should not be stopped during COVID-19 pandemic. Obviously, a careful assessment is mandatory for each individual patient reporting any side effect.

The use of Janus kinase inhibitors in the time of SARS-CoV-2

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment

Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)